A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.
There were plenty of business losers in 2024, but only one for whom the sky was literally falling. In short: Boeing had a bad year.
Luxury brands were riding the subway instead of lounging in limos this year, though a couple of brands were able to buck the trend.
As the dealmaking environment improved in 2024 thanks to the bull market and interest-rate cuts, investment bankers reaped a windfall.